EGLT - Egalet Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.6306
-0.0194 (-2.9846%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.6500
Open0.6691
Bid0.6230 x 1400
Ask0.6700 x 100
Day's Range0.6230 - 0.6795
52 Week Range0.5500 - 4.4800
Volume225,457
Avg. Volume873,384
Market Cap33.331M
Beta-0.06
PE Ratio (TTM)N/A
EPS (TTM)-2.0550
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE20 hours ago

    Free Post Earnings Research Report: Egalet's Q4 Top-Line Growth Beat Estimates

    LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Egalet Corp. (NASDAQ: EGLT). The Company posted its financial results on March 12, 2018, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The Company's quarterly total revenues grew on a y-o-y basis to outshine market forecasts.

  • Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position
    PR Newswire3 days ago

    Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position

    WAYNE, Pa., April 17, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that two large Northeast regional health plans have placed ARYMO® ER (morphine sulfate) extended-release (ER) tablets for oral use only –CII in a preferred formulary position effective immediately. "Obtaining preferred coverage from two large Northeast regional plans that cover nearly a million member lives is a critical step to broadening access to ARYMO ER for those who might need this treatment option," said Patrick Shea, chief commercial officer of Egalet. Please see safety information on ARYMO ER, including the boxed warning and medication guide below.

  • Zacks Small Cap Research19 days ago

    EGLT: Costs Down, Revenues Up, Partnerships Expanding

    The results were distinguished by higher year over year gross margins and expense reductions. Fourth quarter revenues were $7.8 million compared to our $8.8 million estimate and adjusted loss per share of ($0.31) was ahead of our ($0.37) estimate on lower expenses. Fourth quarter operational expenses of $16 million were less than our estimates of $20 million.

  • GlobeNewswire24 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Clifton, CSG Systems International, ArcelorMittal, Denny's, Yamana Gold, and Egalet — New Research Emphasizes Economic Growth

    NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Egalet CEO: 'We are moving the company closer and closer to profitability'
    American City Business Journals29 days ago

    Egalet CEO: 'We are moving the company closer and closer to profitability'

    Specialty pharmaceutical company that received a 'going concern' warning is focused on boosting sales, cutting costs.

  • Auditor raises questions about Egalet's future
    American City Business Journals29 days ago

    Auditor raises questions about Egalet's future

    A report by Ernst & Young noted Eaglet’s outstanding convertible notes contain redemption features in the event the company is not able to maintain its Nasdaq listing.

  • The Wall Street Journal29 days ago

    [$$] Drug Maker Egalet Raises 'Going Concern' warning

    Egalet Corp., a developer of pain-treatment drugs last week raised “substantial doubt” about its ability to “continue as a going concern,” saying its financial condition could weaken if it is unable to ...

  • Egalet to Present at Upcoming Conferences
    PR Newswirelast month

    Egalet to Present at Upcoming Conferences

    WAYNE, Pa., March 21, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that members of the Egalet clinical and development teams will be presenting at two upcoming conferences. Karsten Lindhardt, Ph.D., Egalet's chief scientific officer, will present "The Guardian™ Technology - Injection Molding of Tablets" tomorrow, March 22, at the SMi 15th Annual Controlled Release Delivery Conference in London, England. Colville Brown, M.D., Egalet medical director, will present at the Insight Exchange Network Conference titled, "Responding to the Opioid Crisis: Litigation, Regulation, & Reform" in Philadelphia, PA on April 16 and 17, 2018.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of EGLT earnings conference call or presentation 12-Mar-18 12:30pm GMT

    Q4 2017 Egalet Corp Earnings Call

  • ACCESSWIRElast month

    Egalet Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Egalet Corporation (NASDAQ: EGLT ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 8:30 AM Eastern Time. ...

  • Associated Presslast month

    Egalet posts 4Q profit

    The Wayne, Pennsylvania-based company said it had profit of 3 cents per share. Losses, adjusted to extinguish debt, were 27 cents per share. The pain medicine maker posted revenue of $7.8 million in the ...

  • Egalet Reports Fourth Quarter and Full Year 2017 Financial Results
    PR Newswirelast month

    Egalet Reports Fourth Quarter and Full Year 2017 Financial Results

    -- 120 percent combined prescription growth 2017 over 2016 -- -- 55 percent net product sales growth 2017 over 2016 -- -- Q4 2017 costs and expenses reduced 21 percent from Q3 2017 -- -- Company to host ...

  • Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions
    PR Newswire2 months ago

    Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions

    WAYNE, Pa. , Feb. 28, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing ...

  • Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 12, 2018
    PR Newswire2 months ago

    Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 12, 2018

    WAYNE, Pa., Feb. 26, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that its fourth quarter and year-end 2017 financial results will be released on Monday, March 12, 2018. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

  • Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology
    PR Newswire2 months ago

    Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology

    WAYNE, Pa., Feb. 20, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced it has received a U.S. patent for its proprietary Guardian™ Technology. "The newly issued patent covers our proprietary Guardian Technology which has successfully been tested in clinical studies," said Karsten Lindhardt, Ph.D., chief scientific officer of Egalet. The patent covers the Guardian Technology two-component tablet architecture which provides precise drug delivery and can confer abuse-deterrent properties.

  • Egalet to Participate in Panel at BIO CEO & Investor Conference
    PR Newswire3 months ago

    Egalet to Participate in Panel at BIO CEO & Investor Conference

    WAYNE, Pa., Feb. 1, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that Bob Radie, Egalet president and chief executive officer, will participate in a panel on the opioid crisis at the BIO CEO & Investor Conference in New York city. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO® ER (morphine sulfate) extended-release tablets for oral use —CII, developed using Egalet's proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII and SPRIX® (ketorolac tromethamine) Nasal Spray.

  • Egalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal
    PR Newswire3 months ago

    Egalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal

    WAYNE, Pa., Jan. 29, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that data on ARYMO® ER (morphine sulfate) extended-release (ER) tablets for oral use only –CII was published online in the Current Medical Research and Opinion journal. ARYMO ER, formulated with Egalet's Guardian™ Technology, is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. "The article highlights the importance of understanding the design of abuse-deterrent studies when translating the potential clinical impact of an abuse-deterrent product like ARYMO ER," said Colville Brown, MD, medical director at Egalet.

  • GlobeNewswire3 months ago

    Research Report Identifies Fate Therapeutics, A. Schulman, Celadon Group, Egalet, Meredith, and HCP with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Jan. 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fate ...

  • Egalet to Co-Host Category 1 Focus Group
    PR Newswire3 months ago

    Egalet to Co-Host Category 1 Focus Group

    WAYNE, Pa., Jan. 24, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced it will be co-hosting the 3rd Category 1 Focus Group meeting (part of the Cross Company Abuse Liability Council Non-profit Organization) on January 30 and 31 in Alexandria, VA. "This meeting continues to help advance the field of Category 1 abuse-deterrent studies which is a crucial step in the development of safer opioids," said Karsten Lindhardt, founder of the Category 1 Focus Group and chief scientific officer of Egalet.

  • Egalet's Partner OraPharma Begins Promotion of SPRIX® Nasal Spray
    PR Newswire3 months ago

    Egalet's Partner OraPharma Begins Promotion of SPRIX® Nasal Spray

    -- Doubles the promotional effort behind SPRIX -- WAYNE, Pa. , Jan. 23, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company ...

  • American City Business Journals4 months ago

    Egalet targeting dentists in co-promotion deal with Montco firm

    Egalet Corp. is teaming up with a Montgomery County specialty pharmaceutical company that focuses on oral health in a product co-promotion deal. Under a two-year agreement, Egalet and OraPharma Inc. will co-promote Egalet’s Sprix pain relief medicine delivered as a nasal spray to dentists, dental specialists and oral surgeons across the country.

  • Egalet Partners with OraPharma to Co-Promote SPRIX® Nasal Spray
    PR Newswire4 months ago

    Egalet Partners with OraPharma to Co-Promote SPRIX® Nasal Spray

    WAYNE, Pa. , Jan. 3, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative ...

  • Capital Cube4 months ago

    ETFs with exposure to Egalet Corp. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Egalet Corp. Here are 5 ETFs with the largest exposure to EGLT-US. Comparing the performance and risk of Egalet Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Zacks Small Cap Research4 months ago

    EGLT: Debt Refinancing With Benefits

    The new convertible notes are due December 31, 2024 and are convertible into approximately 750 shares per $1,000 face value, which is equivalent to a conversion price of $1.33.  Currently, Egalet does not have sufficient shares authorized to satisfy a full conversion of the new securities and has created 3.5 million warrants (exercisable at $0.01) as a temporary measure until additional shares are authorized.  If the convertible bonds are exercised prior to authorization of new shares, the warrants will be issued to satisfy the conversion.  Through the exchange, Egalet was able to lower the face value of the debt and lower its net interest expense by reducing the effective conversion price. Egalet offered the exchange to all of the 5.5% convertible bondholders, however, only a portion took advantage of it.  As the units move closer to maturity, we anticipate that Egalet will try to eliminate more of these units coming due in 2020 through exchange at a favorable time or paydown if sufficient cash is available at the time.

  • Egalet Reduces Debt Obligation, Extends Maturity and Lowers Annual Interest Payments through Refinancing of Existing Convertible Notes
    PR Newswire4 months ago

    Egalet Reduces Debt Obligation, Extends Maturity and Lowers Annual Interest Payments through Refinancing of Existing Convertible Notes

    WAYNE, Pa., Dec. 20, 2017 /PRNewswire/ -- Egalet Corporation (EGLT) (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced it has entered into exchange agreements with certain holders of Egalet's outstanding 5.50% senior convertible notes ("Existing Notes") due April 1, 2020. The total principal amount outstanding of the Existing Notes will be reduced, and the maturity date of new notes is December 2024—a five-year extension from the original date. "Through the exchange, we will reduce our debt obligations, extend our maturity date and decrease our annual interest expense, which we believe will improve our capital structure," said Stan Musial, chief financial officer of Egalet.